As the COVID-19 situation evolves, Sol-Gel is committed to protecting the health, safety and welfare of our employees and their families. We have taken the following steps to help mitigate the spread of the coronavirus:

Business Continuity Plan (BCP) and Disaster Recovery Plan (DRP) were in place ahead of the COVID-19 crisis, and our Information Technology (IT) infrastructure allows recovery in case of a disaster including secured remote access to servers.

Purchase orders were placed to increase our current inventory.

Company is following all restrictions published by the Israeli Ministry of Health (IMOH).

SGT-210 Phase I proof-of-concept clinical study is ongoing subject to IMOH guidelines for COVID-19.

All employees returned to work at our facilities.

Company is taking all measures to ensure the well-being of our employees including frequent on-site cleaning and sanitary measures.

All business travel abroad was canceled and replaced with telecoms and video conferences.

EPSOLAY®️ (encapsulated benzoyl peroxide) & TWYNEO®️ (encapsulated benzoyl peroxide and encapsulated tretinoin)

1

We completed the clinical programs required for the submission of our NDAs for Epsolay and Twyneo

2

We also met with the FDA (physically and through telecoms) for pre-NDA meetings

3

Exhibit batches for Epsolay were produced at full commercial scale and the next production step is the manufacture of the commercial/validation batches

4

Exhibit batches for Twyneo were produced on a 200kg scale

Our CMOs (Contract Manufacturer Organizations) for Epsolay and Twyneo are open despite COVID-19.

We therefore do not anticipate delays in the submission of the NDAs or the production of the commercial/validation batches for both Epsolay and Twyneo.

This is of course, a dynamic situation which we will be monitoring closely.

Epsolay and Twyneo are registered trademarks of Sol-Gel Technologies Ltd.